ClinicalTrials.gg
RecruitingNCT04864054ARYA-3Updated Sep 10, 2026

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

A Phase 1/2 interventional study of ECT204 T cells in Hepatocellular Carcinoma, Liver Cancer, Adult and Liver Neoplasm, sponsored by Eureka Therapeutics Inc.. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Eureka Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
268th of 775
60 · median 36
Started
2022
with 50 others
Phase 1/2
112 of 926
29 open now
Primary completion
2027-12
later than 145 of 244 live
Registered
702nd of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 268th largest by planned enrollment of the 775 interventional ones that give a count, is one of 51 that started in 2022, is one of 112 in phase 1/2, reaches primary completion later than 145 of the 244 other live ones, and was the 702nd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.

Read the detailed description

ECT204 is an autologous T-cell product built on the ARTEMIS® Cell Receptor platform, incorporating two GPC3-targeting surface components: an antibody-T-cell receptor (AbTCR) and a chimeric stimulating receptor (CSR). Each subject's T cells are collected and genetically modified ex vivo to co-express these receptors, then re-administered to selectively recognize and eliminate GPC3-expressing HCC tumor cells.

The study consists of a completed Phase 1 and a Phase 2 expansion cohort. Phase 1 used a traditional 3+3 dose-escalation design to determine the recommended Phase 2 dose (RP2D), followed by an RP2D confirmatory cohort to further characterize safety. Phase 2 evaluates a multi-infusion strategy of up to four ECT204 infusions administered across two treatment cycles, with the second cycle administered to subjects who achieve stable disease or better at the Month 2 assessment.

The active assessment period extends for 2 years (24 months) after the first ECT204 infusion (Day 0). Subjects then enter long-term follow-up (LTFU) for ongoing safety and overall survival assessments through Year 15.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Liver Cancer, Adult
  • Liver Neoplasm
  • Metastatic Liver Cancer

Keywords

  • Hepatocellular Carcinoma
  • Advanced HCC
  • Late-Stage HCC
  • Liver Cancer
  • Liver Neoplasm
  • Metastatic Liver Cancer
  • Metastatic HCC
  • T-cell therapy
  • Immunotherapy
  • HCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed HCC, that is unresectable, recurrent, and/or .
  • GPC3-positive tumor expression confirmed by immunohistochemistry (IHC).

    • For the dose-escalation cohort: ≥10-20% tumor cells, ≥2+ IHC.
    • Beginning with the RP2D confirmatory cohort: ≥ 50% tumor cells, 2+/3+ IHC.
  • Must have received at least systemic therapy for HCC and have experienced disease progression on, or intolerance to, that therapy.
  • of at least 4 months per the Investigator's opinion.
  • (ECOG) performance status 0-1.
  • by v1.1.
  • score of A6 or better.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing illness (e.g., symptomatic congestive heart failure) that would limit compliance with study requirements.
  • Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with (HIV), , or are eligible provided their infection is being treated and the viral load is controlled.
  • History of other than HCC within 5 years before screening, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other malignancies with low risk of recurrence.
  • Known or other active central nervous system (CNS) involvement, including . Subjects with brain metastases that have been adequately treated (no evident neurological deficit and no or anti-epileptic therapy for brain metastases) are eligible.
  • Pregnant or lactating women.
  • Currently receiving or ending (\< 14 days from date of consent) liver tumor-directed therapy (e.g., radiation, ablation, embolization), or hepatic surgery.
  • Concurrently receiving other agents, biological, chemical, or radiation therapies, while participating in the study.
  • Active disease requiring systemic therapy.
  • Presence of portal vein tumor thrombus (PVTT) classified as grade Vp4, or any invasion into the inferior vena cava (IVC), except for subjects with IVC invasion who have been treated and radiographically stable for at least 6 months prior to screening.
  • Ascites requiring active treatment, such as a requirement for paracentesis or escalation of diuretic doses. Exception: Subjects maintained on a stable dose of diuretics with controlled, asymptomatic ascites are eligible.
  • Active gastrointestinal (GI) bleeding event ≥ Grade 3 per National Cancer Institute (NCI) Common Terminology for Adverse Events (), version 5.0, within 6 months prior to screening.
  • Coagulation abnormality defined as (INR) > 1.7, unless the elevation is due to therapeutic anticoagulation that, in the Investigator's judgment, can be safely managed in the context of study procedures.
  • History of organ transplant.
  • HCC involving greater than 50% of the liver volume.
  • Experienced allergies to any component of the study drug (ECT204), mouse immunoglobulin, or iron-dextran, or have a history of severe , including anaphylaxis.
  • Previously received other gene therapy (e.g., chimeric antigen receptor T-cell [CAR-T] therapy); exception: prior oncolytic virus therapy is permitted.).
  • for undergoing leukapheresis procedure or receipt of conditioning agents
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Dose Escalation, RP2D Confirmatory, and Expansion (Phase 1/2 Single Arm)

    Dose Escalation Cohort: Participants receive a single infusion of ECT204 at one of four predefined dose levels on Day 0 (completed). RP2D Confirmatory Cohort: Participants receive ECT204 at the RP2D on Day 0 and may receive a second infusion approximately one month later. Expansion Cohort: Participants receive multiple infusions of ECT204 at the RP2D, beginning on Day 0, with subsequent infusions administered according to the protocol-defined schedule.

    Biological: ECT204 T cells

Interventions

  • BiologicalECT204 T cells

    ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of ECT204.

    Type, frequency, and severity of adverse events (AEs), including treatment-emergent AEs (TEAEs), treatment-related AEs (TRAEs), serious adverse events (SAEs), adverse events of special interest (AESIs), clinically significant laboratory abnormalities recorded as AEs, and AEs leading to permanent discontinuation.

    Time frame: Up to 2 years (active assessment period); additional long-term follow-up (LTFU) up to 15 years

Secondary outcomes

  1. To assess the efficacy of ECT204 using RECIST v1.1 | Overall Response Rate (ORR)

    ORR, defined as the proportion of subjects with a best overall response (BOR) of either CR or PR.

    Time frame: Up to 15 years

  2. To assess the efficacy of ECT204 using RECIST v1.1 | Duration of Response (DOR)

    DOR, defined as the time from first documented occurrence of CR or PR to PD or death from any cause, whichever occurs first.

    Time frame: Up to 15 years

  3. To assess the efficacy of ECT204 using RECIST v1.1 | Progression-Free Survival (PFS)

    PFS, defined as the time from first ECT204 infusion to PD or death from any cause, whichever occurs first.

    Time frame: Up to 15 years

  4. To assess the efficacy of ECT204 using RECIST v1.1 | Disease Control Rate (DCR)

    DCR, defined as the proportion of subjects with BOR of CR, PR, or SD.

    Time frame: Up to 15 years

  5. To assess the efficacy of ECT204 using RECIST v1.1 | Time to Response (TTR)

    TTR, defined as the time from first ECT204 infusion to the first documented occurrence of CR or PR, among subjects who achieve an objective response.

    Time frame: Up to 15 years

  6. To assess the efficacy of ECT204 using RECIST v1.1 | Time to Progression (TTP)

    TTP, defined as the time from first ECT204 infusion to PD.

    Time frame: Up to 15 years

  7. To assess the efficacy of ECT204 using RECIST v1.1 | Overall Survival (OS)

    OS, defined as the time from first ECT204 infusion to death from any cause.

    Time frame: Up to 15 years

  8. To evaluate changes in serum GPC3 as a pharmacodynamic marker of ECT204 activity.

    Change from baseline in serum GPC3 over time; association between dynamic changes in serum GPC3 and radiographic tumor response by RECIST v1.1.

    Time frame: Up to 2 years

  9. To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204 | Peak exposure (Cmax)

    Cmax will be determined

    Time frame: Up to 2 years

  10. To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204 | Time to reach peak exposure (Tmax)

    Tmax will be determined

    Time frame: Up to 2 years

  11. To characterize the pharmacokinetic (PK) profile of ECT204, including the expansion and persistence of ECT204 | Area under the concentration-time curve to the last quantifiable concentration (AUCt)

    AUCt will be determined

    Time frame: Up to 2 years

07

Study locations

6 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2027, 69 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 69 months is above that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2021
First posted
Apr 28, 2021
StartActual
Mar 11, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04864054
Lead sponsor
Eureka Therapeutics Inc.
Responsible party
Sponsor
First posted
Apr 28, 2021
Start date
Mar 11, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Teresa Klask, MBA
Contact
Teresa.Klask@eurekainc.com
925-949-9314
Pei Wang, PhD
Contact
Pei.Wang@eurekainc.com
510-654-7045
Pei Wang, PhD
study director · Eureka Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion